Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
US10005772B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10005772-B2 |
| Application number | US-51946307-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 20, 2007 |
| Priority date | Dec 22, 2006 |
| Publication date | Jun 26, 2018 |
| Grant date | Jun 26, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.
Opening claim text (preview).
What is claimed is: 1. An immune response modifier (IRM) conjugate of the Formula: wherein: when taken together, R A and R B form a fused aryl ring wherein the aryl ring is unsubstituted; R 1 is selected from the group consisting of: —R 4 , —X—R 4 , —X—Y—R 4 , —X—Y—X—Y—R 4 , and —X—R 5 ; R 2 is selected from the group consisting of: —R 4 , —X—R 4 , —X—Y—R 4 , and —X—R 5 ; R 3 is selected from the group consisting of: —Z—R 4 , —Z—X—R 4 , —Z—X—Y—R 4 , —Z—X—Y—X—Y—R 4 , and —Z—X—R 5 ; X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more —O— groups; Y is selected from the group consisting of: —O—, —S(O) 0-2 —, —S(O) 2 —N(R 8 )—, —C(R 6 )—, —C(R 6 )—O—, —O—C(R 6 )—, —O—C(O)—O—, —N(R 8 )-Q-, —C(R 6 )—N(R 8 )—, —O—C(R 6 )—N(R 8 )—, —C(R 6 )—N(OR 9 )—, —O—N(R 8 )-Q-, —O—N═C(R 4 )—, —C(═N—O—R 8 )—, —CH(—N(—O—R 8 )-Q-R 4 )—, Z is a bond or —O—; R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo; R 5 is selected from the group consisting of R 6 is selected from the group consisting of ═O and ═S; R 7 is C 2-7 alkylene; R 8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, hydroxyalkylenyl, arylalkylenyl, and heteroarylalkylenyl; R 9 is selected from the group consisting of hydrogen and alkyl; R 10 is C 3-8 alkylene; A is selected from the group consisting of —O—, —C(O)—, —S(O) 0-2 —, and N(R 4 )—; A′ is selected from the group consisting of —O—, —S(O) 0-2 —, —N(-Q-R 4 )—, and —CH 2 —; Q is selected from the group consisting of a bond, —C(R 6 )—, —C(R 6 )—C(R 6 )—, —S(O) 2 —, —C(R 6 )—N(R 8 )—W—, —S(O) 2 —N(R 8 )—, —C(R 6 )—O—, —C(R 6 )—S—, and —C(R 6 )—N(OR 9 )—; V is selected from the group consisting of —C(R 6 )—, —O—C(R 6 )—, —N(R 8 )—C(R 6 )—, and —S(O) 2 —; W is selected from the group consisting of a bond, —C(O)—, and S(O) 2 —; a and b are independently integers from 1 to 6 with the proviso that a+b is ≤7; SAM is a second active moiety wherein the SAM is other than a second IRM moiety; FG C is selected from the group consisting of Linker C is the reaction product of Linker A-FG A and Linker B-FG B ; Linker A is C 1-10 alkylene, alkylene-arylene, arylene-C 1-10 alkylene, C 3 -C 8 heterocyclene, C 1-10 alkylene-C 3-8 heterocyclene, or C 3-8 heterocyclene-C 1-10 alkylene; Linker B is C 1-10 alkylene, O—C 1-8 alkylene-arylene, alkylene-arylene, arylene-C 1-10 alkylene, C 3 -C 8 heterocyclene, alkylene-C 3-8 heterocyclene, or C 3-8 heterocyclene-C 1-10 alkylene; p is an integer from 1 to 20; and FG A and FG B are capable of reacting with each other to form a covalent bond. 2. The conjugate of claim 1 wherein the second active moiety comprises a targeting moiety. 3. The conjugate of claim 2 wherein the targeting moiety comprises an active targeting moiety. 4. The conjugate of claim 3 wherein the targeting moiety comprises an antibody, LHRH receptor ligand, or folic acid receptor ligand. 5. The conjugate of claim 2 wherein the targeting moiety comprises a passive targeting moiety. 6. The conjugate of claim 2 wherein the targeting moiety comprises a nanoparticle having a diameter of from about 50 nm to about 200 nm. 7. The conjugate of claim 1 wherein FG C is 8. The conjugate of claim 1 , wherein FG A is a nucleophilic group that is reactive to FG B , and FG B is an electrophilic group. 9. The conjugate of claim 1 , wherein FG A is an electrophilic group that is reactive to FG B , and FG B is a nucleophilic group. 10. The conjugate of claim 1 , wherein FG A is selected from the group consisting of wherein LG is a leaving group selected from Cl, Br, I, O-mesyl or O-tosyl, and AAG is an acid activating group selected from N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide activated acids, N-hydroxysuccinimide, sulfo-N-hydroxysuccinimide, 4-nitrophenyl, chloride, bromide, anhydride, mixed anhydride, pehtaflurophenyl ester, and tetraflurophenyl ester. 11. The conjugate of claim 1 , wherein FG B is selected from the group consisting of
Drugs for immunological or allergic disorders · CPC title
Brushes where the reservoir is specifically intended for being refilled when empty · CPC title
Curry combs; Brushes (shearing sheep B26B19/24) · CPC title
Ortho-condensed systems · CPC title
Arrangements for preventing undesired leakage or dispensing · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.